Wang Feiyan, Cai Bo, Wang Li, Gu Zhenyang, Luo Lan, Wei Huaping, Zhao Shasha, Guan Lixun, Wang Xiaoyu, Wang Lili, Liu Daihong, Gao Chunji
Department of Haematology, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China (mainland).
Department of Haematology, The 307th Hospital of Chinese People's Liberation Army, Beijing, China (mainland).
Ann Transplant. 2017 Feb 3;22:58-65. doi: 10.12659/aot.901495.
BACKGROUND Acute graft-versus-host disease (aGVHD) remains the most common and challenging complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). An important obstacle to the therapeutic effect of aGVHD is the inability to identify risk factors for an individual patient at the onset of symptoms. We performed a retrospective study with the aim of defining clinically meaningful pre-transplantation risk factors for grades II-IV aGVHD patients. MATERIAL AND METHODS To identify pre-transplantation risk factors for grades II-IV aGVHD after allo-HSCT, we performed a retrospective study in 292 patients who underwent allo-HSCT at our center from January 2010 to July 2015. RESULTS The cumulative incidence of grades II-IV aGVHD was 36.6±2.8%. The most common target organ of aGVHD was the skin (46.7%), followed by the gastrointestinal tract (29.9%). The risk factors we identified included HLA-mismatched related donors (odds ratio [OR], 3.21; 95% confidence interval [CI], 1.82-5.67) and conditioning regimens containing TBI but no ATG (OR, 2.66; 95% CI, 1.40-5.06). Simultaneously, transplantation with an identical sibling donor (OR, 0.31; 95% CI, 0.18-0.55) and the use of ATG in the conditioning regimen containing TBI (OR 0.37; 95% CI, 0.15-0.93) were two factors found to be associated with a decreased risk of grades II-IV aGVHD. CONCLUSIONS Our study suggests that pre-transplantation characteristics of donor and recipient play an important role in identifying patients at high risk for grades II-IV aGVHD, which provide a direction for the prevention and treatment of aGVHD in the future.
背景 急性移植物抗宿主病(aGVHD)仍然是异基因造血干细胞移植(allo-HSCT)后最常见且具有挑战性的并发症。aGVHD治疗效果的一个重要障碍是在症状出现时无法识别个体患者的危险因素。我们进行了一项回顾性研究,旨在确定II-IV级aGVHD患者具有临床意义的移植前危险因素。 材料与方法 为了识别allo-HSCT后II-IV级aGVHD的移植前危险因素,我们对2010年1月至2015年7月在本中心接受allo-HSCT的292例患者进行了回顾性研究。 结果 II-IV级aGVHD的累积发病率为36.6±2.8%。aGVHD最常见的靶器官是皮肤(46.7%),其次是胃肠道(29.9%)。我们确定的危险因素包括HLA不匹配的相关供者(比值比[OR],3.21;95%置信区间[CI],1.82-5.67)和含全身照射(TBI)但不含抗胸腺细胞球蛋白(ATG)的预处理方案(OR,2.66;95%CI,1.40-5.06)。同时,与同卵同胞供者进行移植(OR,0.31;95%CI,0.18-0.55)以及在含TBI的预处理方案中使用ATG(OR 0.37;95%CI,0.15-0.93)是发现的与降低II-IV级aGVHD风险相关的两个因素。 结论 我们的研究表明,供者和受者的移植前特征在识别II-IV级aGVHD高危患者中起重要作用,这为未来aGVHD的预防和治疗提供了方向。